EPS for Geron (GERN) Expected At $-0.04; Cyrus Capital Partners LP Has Lowered By $33.35 Million Its Ally Finl (ALLY) Stake

February 17, 2018 - By Ellis Scott

Analysts expect Geron Corporation (NASDAQ:GERN) to report $-0.04 EPS on March, 7.They anticipate $0.01 EPS change or 20.00% from last quarter’s $-0.05 EPS. After having $-0.04 EPS previously, Geron Corporation’s analysts see 0.00% EPS growth. It closed at $2.38 lastly. It is down 13.81% since February 17, 2017 and is uptrending. It has underperformed by 2.89% the S&P500.

Cyrus Capital Partners Lp decreased Ally Finl Inc (ALLY) stake by 15.27% reported in 2017Q3 SEC filing. Cyrus Capital Partners Lp sold 1.39 million shares as Ally Finl Inc (ALLY)’s stock declined 19.04%. The Cyrus Capital Partners Lp holds 7.71M shares with $187.12M value, down from 9.10M last quarter. Ally Finl Inc now has $12.53 billion valuation. The stock decreased 0.21% or $0.06 during the last trading session, reaching $28.67. About 1.57M shares traded. Ally Financial Inc. (NYSE:ALLY) has risen 12.72% since February 17, 2017 and is uptrending. It has underperformed by 3.98% the S&P500.




Among 23 analysts covering Ally Financial (NYSE:ALLY), 16 have Buy rating, 1 Sell and 6 Hold. Therefore 70% are positive. Ally Financial had 61 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Underweight” rating given on Monday, July 17 by Stephens. On Wednesday, January 31 the stock rating was maintained by Credit Suisse with “Outperform”. The stock of Ally Financial Inc. (NYSE:ALLY) earned “Buy” rating by Piper Jaffray on Wednesday, August 30. The firm earned “Buy” rating on Wednesday, October 25 by BTIG Research. The firm has “Outperform” rating by Credit Suisse given on Thursday, October 26. The company was maintained on Wednesday, January 31 by Wells Fargo. BMO Capital Markets downgraded the shares of ALLY in report on Wednesday, January 31 to “Market Perform” rating. The stock of Ally Financial Inc. (NYSE:ALLY) has “Overweight” rating given on Tuesday, January 2 by Barclays Capital. The firm has “Buy” rating by BTIG Research given on Tuesday, January 16. The firm has “Buy” rating by Keefe Bruyette & Woods given on Thursday, July 27.

Geron Corporation operates as a biopharmaceutical company. The company has market cap of $378.97 million. The firm supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It currently has negative earnings. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.